Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06132087 · ClinicalTrials.gov registry record · NA
PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy
A NA study of Locally Advanced Pancreatic Adenocarcinoma and Unresectable Pancreatic Adenocarcinoma, sponsored by University of Southern California.
- Active
- Registry status
- NA
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT06132087: Active NA study of Locally Advanced Pancreatic Adenocarcinoma and Unresectable Pancreatic Adenocarcinoma, sponsored by University of Southern California.
NCT06132087 is a NA study of Locally Advanced Pancreatic Adenocarcinoma and Unresectable Pancreatic Adenocarcinoma that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 2 participants, below the 67-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06132087, a NA study of Locally Advanced Pancreatic Adenocarcinoma and Unresectable Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by University of Southern California.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial tests how well surgical resection after chemotherapy given before surgery to make the tumor smaller (neoadjuvant) works to treat pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) and that cannot be removed by surgery (unresectable). In general, surgery is considered the most effective treatment for pancreatic cancer, especially when the cancer is localized and has not spread to other organs. However, most patients with pancreatic cancer are not candidates for surgical removal because the cancer has grown into or close to nearby arteries, veins, or organs and there is a concern of damaging these nearby structures. Researchers want to find out if surgery after neoadjuvant chemotherapy can be done safely to completely remove the tumor in patients with locally advanced and unresectable pancreatic cancer.
Primary Outcome
Will be defined as the proportion of patients with negative resection margins after undergoing surgery.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Distal Pancreatectomy
- PROCEDURE Laparoscopy
Study Locations (1)
California
- USC / Norris Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-12-01 |
| Est. Completion | 2028-12-01 |
| Phase | NA |
What the registry record for NCT06132087 still lists
NCT06132087 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 67-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Locally Advanced Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06132087 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06132087 about?
NCT06132087 is a clinical study titled "PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy". This clinical trial tests how well surgical resection after chemotherapy given before surgery to make the tumor smaller (neoadjuvant) works to treat pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) and that cannot be removed by surgery (unresectable). In general, ...
What is the current status of trial NCT06132087?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 2 participants. The study started on 2023-12-01. Estimated completion is 2028-12-01.
What conditions does trial NCT06132087 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer American Joint Committee on Cancer v8.
What interventions are being tested in trial NCT06132087?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Distal Pancreatectomy (PROCEDURE), Laparoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT06132087?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06132087 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06132087's enrollment target sits among peer trials
2 19th of 18 the lowest of 18 other Locally Advanced Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Locally Advanced Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
RECRUITING · NA
-
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
RECRUITING · Phase 1
-
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
RECRUITING · Phase 3
-
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI